What is GHRP-2 (pralmorelin)?
GHRP-2 is a synthetic peptide that binds the ghrelin receptor (GHS-R1a) in the pituitary and triggers a strong release of growth hormone (GH). It was the first drug of this class to be used clinically.
How well studied is GHRP-2 (pralmorelin)?
In Japan, pralmorelin is used as a diagnostic agent to test for growth hormone deficiency. Therapeutic uses (GH deficiency, short stature) did not progress beyond phase II; there are no solid human data on muscle gain, fat loss or anti-aging.
What side effects and risks does GHRP-2 (pralmorelin) have?
Reliably causes strong hunger and can raise cortisol and prolactin as well as GH. Persistently elevated GH/IGF-1 levels can promote fluid retention, joint pain and worse blood sugar control. Long-term safety outside diagnostic use has not been studied; grey-market products are untested for purity and sterility.
Is GHRP-2 (pralmorelin) approved in Germany?
In short: no – only outside the EU. Approved only in Japan as a diagnostic agent; not approved in the EU/Germany. Prohibited in sport (WADA S2, GH-releasing peptides); GH secretagogues may also fall under the German Anti-Doping Act (AntiDopG). Products sold as “research chemicals” are not quality-controlled.
Sources
Note: We deliberately do not list any doses here. For approved medicines, your doctor sets the dose; for unapproved substances there is no reliable information.